Actavis plc is purchasing infectious disease specialist Durata Therapeutics Inc. for $23 per share in cash, or approximately $675 million, plus contingent value rights (CVR) of up to $5 per share in additional cash payments linked to regulatory and commercial milestones for Durata's lead product, Dalvance (dalbavancin).